GE Healthcare, a subsidiary of General Electric (GE), has acquired Biosafe Group, a supplier of integrated cell bioprocessing systems based in Lake Geneva, Switzerland, for an undisclosed sum. The acquisition expands GE Healthcare's products, solutions, and services for cell therapy, as well as its technology for new cell and therapy types.

The acquisition will combine biological, engineering, and industrial capabilities for cell therapy and cellular immunotherapy. Biosafe, founded in 1997, designs, manufactures, and markets automated cell-processing systems used in bioprocessing, regenerative medicine, and stem-cell banking. Cellular therapies provide treatments for challenging diseases such as cancer.

In 2016, GE announced further investments in cell therapy and regenerative medicine, including a $31.5 million co-investment with the Canadian government in BridGE@CCRM, a center to promote new technologies for producing cellular therapies in Toronto. Its GE Ventures subsidiary also launched a platform company called Vitruvian Networks with the Mayo Clinic for access to cell and gene therapies through cloud-ready software systems and manufacturing services.

Source: GE Healthcare